Biosite plans further data as FDA panel rejects heart test
This article was originally published in Clinica
Rapid test manufacturer Biosite Diagnostics has said it could file an amended PMA for US approval of its Triage BNP diagnostic for heart failure as early as late summer. The company's original application was rejected by an FDA advisory panel on March 24 by six votes to three after "major concerns" with the clinical data from US trials. The agency normally follows its panel's advice.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.